Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
Clearmind Medicine (Nasdaq: CMND) announced receipt of a notice of patent publication from the China National Intellectual Property Administration dated November 12, 2025, covering its proprietary non‑hallucinogenic compound 5‑methoxy‑2‑aminoindane (MEAI) for the treatment of depression.
The release notes that preclinical studies show MEAI may enhance mood regulation and reduce anhedonia, and that the patent application expands Clearmind’s intellectual property protections for MEAI across multiple jurisdictions and for several mental health and addiction indications.
Clearmind Medicine (Nasdaq: CMND) ha annunciato di aver ricevuto un avviso di pubblicazione della patente dall'Amministrazione nazionale della proprietà intellettuale cinese datato 12 novembre 2025, che copre il proprio composto non allucinogeno 5-metossi-2-aminoindano (MEAI) per il trattamento della depressione.
Il comunicato osserva che studi preclinici mostrano che MEAI può migliorare la regolazione dell'umore e ridurre l'anhédonie, e che la richiesta di brevetto amplia le protezioni della proprietà intellettuale di Clearmind per MEAI in diverse giurisdizioni e per diverse indicazioni legate alla salute mentale e alla dipendenza.
Clearmind Medicine (Nasdaq: CMND) anunció haber recibido un aviso de publicación de patente de la Administración Nacional de Propiedad Intelectual de China con fecha 12 de noviembre de 2025, que cubre su compuesto no alucinógeno propio 5-metoxi-2-aminoindano (MEAI) para el tratamiento de la depresión.
El comunicado señala que estudios preclínicos muestran que MEAI puede mejorar la regulación del estado de ánimo y reducir la anhedonia, y que la solicitud de patente amplía las protecciones de propiedad intelectual de Clearmind para MEAI en múltiples jurisdicciones y para varias indicaciones de salud mental y adicción.
클리어마인드 메디슨(나스닥: CMND)은 2025년 11월 12일 자로 중국 국가 지적 재산권 관리국으로부터 특허 출판 통지를 접수했다는 소식을 발표했다. 이는 독점적 비환각성 화합물 5-메톡시-2-아미노인덴(MEAI)을 우울증 치료에 적용하기 위한 것이다.
보도자료에 따르면 전임상 연구가 MEAI가 기분 조절을 향상시키고 무즐거움 상실(무쾌감 증상)을 줄일 수 있다고 시사하며, 특허 출원이 MEAI에 대한 Clearmind의 지적 재산권 보호를 여러 관할권 및 여러 정신 건강 및 중독 적응증으로 확장한다고 한다.
Clearmind Medicine (Nasdaq: CMND) a annoncé la réception d’un avis de publication de brevet de l’Administration nationale de la propriété intellectuelle de Chine daté du 12 novembre 2025, couvrant son composé propriétaire non hallucinogène 5-méthoxy-2-aminoindane (MEAI) pour le traitement de la dépression.
Le communiqué précise que des études précliniques montrent que le MEAI peut améliorer la régulation de l’humeur et réduire l’anhédonie, et que la demande de brevet étend les protections de propriété intellectuelle de Clearmind pour MEAI dans plusieurs juridictions et pour plusieurs indications liées à la santé mentale et à la dépendance.
Clearmind Medicine (Nasdaq: CMND) kündigte den Erhalt einer Patentanmeldungsbenachrichtigung von der China National Intellectual Property Administration an, datiert auf den 12. November 2025, die seinen eigenen nicht-halluzinogenen Wirkstoff 5-Methoxy-2-Aminindan (MEAI) zur Behandlung von Depressionen abdeckt.
Die Mitteilung verweist darauf, dass präklinische Studien zeigen, dass MEAI die Stimmungsregulation verbessern und Hedonieverlust verringern kann, und dass der Patentantrag Clearminds Schutz des geistigen Eigentums für MEAI in mehreren Rechtsordnungen und für verschiedene Indikationen im Bereich psychische Gesundheit und Sucht erweitert.
Clearmind Medicine (Nasdaq: CMND) أعلنت عن استلامها إشعار نشر البراءة من إدارة الملكية الفكرية الوطنية في الصين بتاريخ 12 نوفمبر 2025، يغطي مركّبها غير الهلوسيوني المملوك 5-ميثوكسي-2-أمينوإندين (MEAI) لعلاج الاكتئاب.
وتنص النشرة على أن الدراسات قبل السريرية تُظهر أن MEAI قد يعزز تنظيم المزاج ويقلل من فقدان المتعة (انهدونيا)، وأن طلب البراءة يوسع حماية الملكية الفكرية لـ Clearmind لـ MEAI عبر عدة اختصاصات ولإشارات عدة للصحة النفسية والإدمان.
- Notice of patent publication for MEAI in China
- Preclinical data indicate mood regulation and reduced anhedonia
- Expanded IP portfolio across multiple jurisdictions
- Patent publication is not the same as an issued patent
- Evidence cited is preclinical only; no clinical efficacy reported
- No timelines provided for clinical trials or regulatory milestones
The notice was received by the China National Intellectual Property Administration
Vancouver, Canada, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced notice of publication by the China National Intellectual Property Administration, referring to the Company’s proprietary non hallucinogenic compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression.
According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. This patent application further reinforces Clearmind’s robust IP portfolio, which now includes protections across multiple jurisdictions for MEAI’s applications in various mental health and addiction disorders.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on November 12, 2025 about MEAI?
Does the November 12, 2025 patent publication mean MEAI is approved for depression?
What clinical evidence did Clearmind cite for MEAI in the November 12, 2025 release?
How does the China patent publication affect Clearmind’s intellectual property position (CMND)?
Will the November 12, 2025 patent publication for MEAI speed up clinical development for CMND?
